Strain Name:

NOD.129S2(B6)-Ciitatm1Ccum/FlvJ

Stock Number:

004448

Order this mouse

Availability:

Cryopreserved - Ready for recovery

Use Restrictions Apply, see Terms of Use

Description

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Former Names NOD.129S2(B6)-C2tatm1Ccum/FlvJ    (Changed: 26-MAR-07 )
Type Congenic; Mutant Strain; Targeted Mutation;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Additional information on Congenic nomenclature.
Specieslaboratory mouse
Background Strain NOD
Donor Strain 129S2 via D3 ES cell line
H2 Haplotypeg7
 
Donating InvestigatorDr. Richard A. Flavell,   Yale University School of Medicine

Appearance
albino, pink-eyed
Related Genotype: A/A TyrcTyrc

Description
In humans, a non-functional C2ta (or Ciita) gene causes bare lymphocyte syndrome (BLS), which is characterized by the lack of HLA class II gene expression and a reduced number of mature CD4+ T cells in the periphery.

On the C57BL/6 congenic background (see Stock No. 003239) disruption of C2ta results in a lack of MHC Class II expression by splenic B cells, dendridic cells, and both resting and interferon gamma stimulated macrophages. However, thymic epithelium retains MHC class II expression. Homozygotes also exhibit a significant decrease in the levels of invariant chain and H-2M gene transcripts. Non-conventional MHC Class II molecules such as H-2O alpha and H-2O beta, are not affected by the disruption of C2ta. Despite the continued expression of MHC Class II molecules on cells of the thymic epithilium, few CD4 positive cells exist in the periphery of homozygotes. (Chang et al 1996)

Because of the role of CD4+ T cells in the onset of diabetes, the mutation was backcrossed onto the NOD/ShiLtJ background to characterize its impact on diabetes development. The resulting congenic mice (Stock No. 004448) homozygous for the mutation are completely protected from diabetes after 35 weeks of age. However, they do exhibit perivascular infiltration or periinsulitis at 15 weeks of age.. Like their C57BL/6 counterparts, NOD homozygotes exhibit a ten-fold decrease in CD4+ T cells in the periphery, while the number of CD8+ T cells in the spleen remains normal. Homozygous mice do not show defects in B cell function, as measured by immunoglobulin production after stimulation of B cells with Il4 in vitro. (Mora et al. 1999)

Development
The C2ta (or Ciita) gene was isolated from a 129S2/SvPas genomic library and disrupted by replacement of exons critical for gene function with a neomycin resistance cassette. The vector containing disrupted C2ta was transfected into D3 ES cells (129S2/SvPas derived). Positive clones were injected into C57BL/6 blastocysts, and resulting chimeric mice were intercrossed to produce homozygotes. These homozygous individuals were backcrossed to C57BL/6 for at least 2 generations before being backcrossed to NOD/LtJ for 11 generations using PCR-assisted selection for NOD diabetes susceptibility loci. (Chang et al 1996, Mora et al 1999)

Control Information

  Control
   001976 NOD/ShiLtJ
 
  Considerations for Choosing Controls

Related Strains

Strains carrying   Ciitatm1Ccum allele
003239   B6.129S2-Ciitatm1Ccum/J
003238   C.129S2(B6)-Ciitatm1Ccum/J
005356   NOD.129(B6)-B2mtm1Unc Ciitatm1Ccum/BhsJ
View Strains carrying   Ciitatm1Ccum     (3 strains)

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI
- No similarity to the expected human disease phenotype was found. One or more human genes are associated with this human disease. The mouse genotype may involve mutations to orthologs of one or more of these genes, but the phenotype did not resemble the disease.
Diabetes Mellitus, Insulin-Dependent; IDDM
- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested.
Bare Lymphocyte Syndrome, Type II   (CIITA)
Rheumatoid Arthritis; RA   (CIITA)
View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

Ciitatm1Ccum/Ciitatm1Ccum

        NOD.129S2(B6)-Ciitatm1Ccum
  • homeostasis/metabolism phenotype
  • abnormal circulating glucose level
    • on the NOD background, by 35 weeks of age and later, no mutants show hyperglycemia while 40% of NOD-sufficient mice develop diabetes by 35 weeks of age   (MGI Ref ID J:106081)
  • immune system phenotype
  • abnormal T cell differentiation   (MGI Ref ID J:106081)
  • abnormal inflammatory response   (MGI Ref ID J:106081)
    • pancreas inflammation
      • female mutants show pancreatic infiltration by 15 weeks of age   (MGI Ref ID J:106081)
      • insulitis
        • when recovered from NOD diabetic female recipients, islet grafts obtained from these class II-deficient NOD mice show severe infiltration and lack almost all insulin production   (MGI Ref ID J:107051)
      • periinsulitis
        • at 15 weeks of age, around 2% of islets in female mutants show perinsulitis or insulitis compared with 75% in pre-diabetic and diabetic mice   (MGI Ref ID J:106081)
  • abnormal level of surface class II molecules
    • MHC class II molecule expression is almost completely absent from spleen cells   (MGI Ref ID J:106081)
  • decreased CD4-positive, alpha beta T cell number
    • a 10-fold reduction in levels of peripheral CD4+ T cells is observed compared to controls   (MGI Ref ID J:106081)
  • decreased susceptibility to autoimmune diabetes
    • mice do not develop diabetes (2 consecutive blood glucose measures >16.5 nM) up to 30 weeks of age   (MGI Ref ID J:107051)
  • increased CD8-positive, alpha-beta T cell number
    • CD8+ T cells are slightly over-represented in mutants (25%) compared to controls (16%)   (MGI Ref ID J:106081)
  • hematopoietic system phenotype
  • abnormal T cell differentiation   (MGI Ref ID J:106081)
  • abnormal level of surface class II molecules
    • MHC class II molecule expression is almost completely absent from spleen cells   (MGI Ref ID J:106081)
  • decreased CD4-positive, alpha beta T cell number
    • a 10-fold reduction in levels of peripheral CD4+ T cells is observed compared to controls   (MGI Ref ID J:106081)
  • increased CD8-positive, alpha-beta T cell number
    • CD8+ T cells are slightly over-represented in mutants (25%) compared to controls (16%)   (MGI Ref ID J:106081)
  • endocrine/exocrine gland phenotype
  • pancreas inflammation
    • female mutants show pancreatic infiltration by 15 weeks of age   (MGI Ref ID J:106081)
    • insulitis
      • when recovered from NOD diabetic female recipients, islet grafts obtained from these class II-deficient NOD mice show severe infiltration and lack almost all insulin production   (MGI Ref ID J:107051)
    • periinsulitis
      • at 15 weeks of age, around 2% of islets in female mutants show perinsulitis or insulitis compared with 75% in pre-diabetic and diabetic mice   (MGI Ref ID J:106081)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Diabetes and Obesity Research
Type 1 Diabetes (IDDM) Analysis Strains
      NOD/ShiLtJ Non-MHC Congenics

Immunology, Inflammation and Autoimmunity Research
Immunodeficiency
      MHC class II associated invariant chain deficient
      MHC class II defects
      MHC class II deficient
      T cell deficiency

Internal/Organ Research
Lymphoid Tissue Defects
      T cell deficiency

Research Tools
Immunology, Inflammation and Autoimmunity Research
      MHC class II associated invariant chain deficiency
      MHC class II defects
      T cell deficiency

Ciitatm1Ccum related

Immunology, Inflammation and Autoimmunity Research
Immunodeficiency

Research Tools
Immunology, Inflammation and Autoimmunity Research
      MHC class II defects

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Ciitatm1Ccum
Allele Name targeted mutation 1, Cheong-Hee Chang
Allele Type Targeted (Null/Knockout)
Common Name(s) C2tatm1Ccum; CIITA C-; CIITA-; MHC classII-;
Mutation Made ByDr. Cheong-Hee Chang,   Indiana University
Strain of Origin129S2/SvPas
ES Cell Line NameD3
ES Cell Line Strain129S2/SvPas
Gene Symbol and Name Ciita, class II transactivator
Chromosome 16
Gene Common Name(s) C2TA; C2ta; CIITAIV; EG669998; Gm9475; MHC2TA; NLRA; predicted gene 9475; predicted gene, EG669998;
Molecular Note A genomic fragment containing exons which encode critical regions of the protein was replaced with a neomycin selection gene. Northern blot analysis on RNA derived from homozygous mice demonstrated that no detectable protein was produced from this allele. [MGI Ref ID J:31601]

Genotyping

Genotyping Information

Genotyping Protocols

Ciitatm1Ccum, Standard PCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Additional References

Chang CH; Guerder S; Hong SC; van Ewijk W; Flavell RA. 1996. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression. Immunity 4(2):167-78. [PubMed: 8624807]  [MGI Ref ID J:31601]

Muhlethaler-Mottet A; Otten LA; Steimle V; Mach B. 1997. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J 16(10):2851-60. [PubMed: 9184229]  [MGI Ref ID J:40766]

Ciitatm1Ccum related

Aichinger M; Wu C; Nedjic J; Klein L. 2013. Macroautophagy substrates are loaded onto MHC class II of medullary thymic epithelial cells for central tolerance. J Exp Med 210(2):287-300. [PubMed: 23382543]  [MGI Ref ID J:196474]

Benito AI; Milner LA; Leisenring W; Deeg HJ; Woolfrey AE. 2001. Absence of major histocompatibility class II expression does not impair hematopoiesis in mice. Exp Hematol 29(9):1070-5. [PubMed: 11532347]  [MGI Ref ID J:111611]

Benlagha K; Park SH; Guinamard R; Forestier C; Karlsson L; Chang CH; Bendelac A. 2004. Mechanisms governing B cell developmental defects in invariant chain-deficient mice. J Immunol 172(4):2076-83. [PubMed: 14764672]  [MGI Ref ID J:87989]

Broxmeyer HE; Cooper S; Hangoc G; Chang CH. 2006. Class II transactivator-mediated regulation of major histocompatibility complex class II antigen expression is important for hematopoietic progenitor cell suppression by chemokines and iron-binding proteins. Exp Hematol 34(8):1078-84. [PubMed: 16863914]  [MGI Ref ID J:111903]

Buch T; Polic B; Clausen BE; Weiss S; Akilli-Ozturk O; Chang CH; Flavell R; Schulz A; Jonjic S; Waisman A; Forster I. 2006. MHC class II expression through a hitherto unknown pathway supports T helper cell-dependent immune responses: implications for MHC class II deficiency. Blood 107(4):1434-44. [PubMed: 16254146]  [MGI Ref ID J:129309]

Chang CH; Guerder S; Hong SC; van Ewijk W; Flavell RA. 1996. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression. Immunity 4(2):167-78. [PubMed: 8624807]  [MGI Ref ID J:31601]

Chen L; Jay DC; Fairbanks JD; He X; Jensen PE. 2011. An MHC class Ib-restricted CD8+ T cell response to lymphocytic choriomeningitis virus. J Immunol 187(12):6463-72. [PubMed: 22084437]  [MGI Ref ID J:180389]

Choi EY; Jung KC; Park HJ; Chung DH; Song JS; Yang SD; Simpson E; Park SH. 2005. Thymocyte-thymocyte interaction for efficient positive selection and maturation of CD4 T cells. Immunity 23(4):387-96. [PubMed: 16226504]  [MGI Ref ID J:113276]

Chou SD; Khan AN; Magner WJ; Tomasi TB. 2005. Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells. Int Immunol 17(11):1483-94. [PubMed: 16210330]  [MGI Ref ID J:104221]

Clausen BE; Waldburger JM; Schwenk F; Barras E; Mach B; Rajewsky K; Forster I; Reith W. 1998. Residual MHC class II expression on mature dendritic cells and activated B cells in RFX5-deficient mice. Immunity 8(2):143-55. [PubMed: 9491996]  [MGI Ref ID J:67941]

Creusot RJ; Yaghoubi SS; Kodama K; Dang DN; Dang VH; Breckpot K; Thielemans K; Gambhir SS; Fathman CG. 2008. Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice. Clin Immunol 127(2):176-87. [PubMed: 18337172]  [MGI Ref ID J:133579]

Das G; Das J; Eynott P; Zhang Y; Bothwell AL; Van Kaer L; Shi Y. 2006. Pivotal roles of CD8+ T cells restricted by MHC class I-like molecules in autoimmune diseases. J Exp Med 203(12):2603-11. [PubMed: 17088432]  [MGI Ref ID J:124622]

Devoss JJ; Shum AK; Johannes KP; Lu W; Krawisz AK; Wang P; Yang T; Leclair NP; Austin C; Strauss EC; Anderson MS. 2008. Effector mechanisms of the autoimmune syndrome in the murine model of autoimmune polyglandular syndrome type 1. J Immunol 181(6):4072-9. [PubMed: 18768863]  [MGI Ref ID J:139094]

Elliott EA; Drake JR; Amigorena S; Elsemore J; Webster P; Mellman I; Flavell RA. 1994. The invariant chain is required for intracellular transport and function of major histocompatibility complex class II molecules. J Exp Med 179(2):681-94. [PubMed: 8294875]  [MGI Ref ID J:65917]

Eppert BL; Wortham BW; Flury JL; Borchers MT. 2013. Functional characterization of T cell populations in a mouse model of chronic obstructive pulmonary disease. J Immunol 190(3):1331-40. [PubMed: 23264660]  [MGI Ref ID J:192605]

Fikrig E; Barthold SW; Chen M; Chang CH; Flavell RA. 1997. Protective antibodies develop, and murine Lyme arthritis regresses, in the absence of MHC class II and CD4+ T cells. J Immunol 159(11):5682-6. [PubMed: 9548512]  [MGI Ref ID J:109903]

Gourley T; Roys S; Lukacs NW; Kunkel SL; Flavell RA; Chang CH. 1999. A novel role for the major histocompatibility complex class II transactivator CIITA in the repression of IL-4 production. Immunity 10(3):377-86. [PubMed: 10204493]  [MGI Ref ID J:54057]

Gourley TS; Patel DR; Nickerson K; Hong SC; Chang CH. 2002. Aberrant expression of Fas ligand in mice deficient for the MHC class II transactivator. J Immunol 168(9):4414-9. [PubMed: 11970984]  [MGI Ref ID J:112146]

Green EA; Wong FS; Eshima K; Mora C; Flavell RA. 2000. Neonatal tumor necrosis factor alpha promotes diabetes in nonobese diabetic mice by CD154-independent antigen presentation to CD8(+) T cells. J Exp Med 191(2):225-38. [PubMed: 10637268]  [MGI Ref ID J:59409]

Guleria I; Gubbels Bupp M; Dada S; Fife B; Tang Q; Ansari MJ; Trikudanathan S; Vadivel N; Fiorina P; Yagita H; Azuma M; Atkinson M; Bluestone JA; Sayegh MH. 2007. Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin Immunol 125(1):16-25. [PubMed: 17627890]  [MGI Ref ID J:125272]

Hinterberger M; Aichinger M; da Costa OP; Voehringer D; Hoffmann R; Klein L. 2010. Autonomous role of medullary thymic epithelial cells in central CD4(+) T cell tolerance. Nat Immunol 11(6):512-9. [PubMed: 20431619]  [MGI Ref ID J:160615]

Jay DC; Reed-Loisel LM; Jensen PE. 2008. Polyclonal MHC Ib-Restricted CD8+ T Cells Undergo Homeostatic Expansion in the Absence of Conventional MHC-Restricted T Cells. J Immunol 180(5):2805-14. [PubMed: 18292501]  [MGI Ref ID J:131725]

Kuipers H; Soullie T; Hammad H; Willart M; Kool M; Hijdra D; Hoogsteden HC; Lambrecht BN. 2009. Sensitization by intratracheally injected dendritic cells is independent of antigen presentation by host antigen-presenting cells. J Leukoc Biol 85(1):64-70. [PubMed: 18923103]  [MGI Ref ID J:143272]

Kupfer TM; Crawford ML; Pham K; Gill RG. 2005. MHC-mismatched islet allografts are vulnerable to autoimmune recognition in vivo. J Immunol 175(4):2309-16. [PubMed: 16081800]  [MGI Ref ID J:107508]

Lauvau G; Vijh S; Kong P; Horng T; Kerksiek K; Serbina N; Tuma RA; Pamer EG. 2001. Priming of memory but not effector CD8 T cells by a killed bacterial vaccine. Science 294(5547):1735-9. [PubMed: 11721060]  [MGI Ref ID J:133596]

Lee YJ; Jeon YK; Kang BH; Chung DH; Park CG; Shin HY; Jung KC; Park SH. 2010. Generation of PLZF+ CD4+ T cells via MHC class II-dependent thymocyte-thymocyte interaction is a physiological process in humans. J Exp Med 207(1):237-46, S1-7. [PubMed: 20038602]  [MGI Ref ID J:156545]

Li W; Kim MG; Gourley TS; McCarthy BP; Sant'Angelo DB; Chang CH. 2005. An alternate pathway for CD4 T cell development: thymocyte-expressed MHC class II selects a distinct T cell population. Immunity 23(4):375-86. [PubMed: 16226503]  [MGI Ref ID J:113275]

Li W; Sofi MH; Yeh N; Sehra S; McCarthy BP; Patel DR; Brutkiewicz RR; Kaplan MH; Chang CH. 2007. Thymic selection pathway regulates the effector function of CD4 T cells. J Exp Med 204(9):2145-57. [PubMed: 17724129]  [MGI Ref ID J:126084]

Ling W; Zhang J; Yuan Z; Ren G; Zhang L; Chen X; Rabson AB; Roberts AI; Wang Y; Shi Y. 2014. Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment. Cancer Res 74(5):1576-87. [PubMed: 24452999]  [MGI Ref ID J:208149]

Mora C; Wong FS; Chang CH; Flavell RA. 1999. Pancreatic infiltration but not diabetes occurs in the relative absence of MHC class II-restricted CD4 T cells: studies using NOD/CIITA-deficient mice. J Immunol 162(8):4576-88. [PubMed: 10201997]  [MGI Ref ID J:106081]

Ochi A; Nguyen AH; Bedrosian AS; Mushlin HM; Zarbakhsh S; Barilla R; Zambirinis CP; Fallon NC; Rehman A; Pylayeva-Gupta Y; Badar S; Hajdu CH; Frey AB; Bar-Sagi D; Miller G. 2012. MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J Exp Med 209(9):1671-87. [PubMed: 22908323]  [MGI Ref ID J:191814]

Otten LA; Leibundgut-Landmann S; Huarte J; Kos-Braun IC; Lavanchy C; Barras E; Borisch B; Steimle V; Acha-Orbea H; Reith W. 2006. Revisiting the specificity of the MHC class II transactivator CIITA in vivo. Eur J Immunol 36(6):1548-58. [PubMed: 16703565]  [MGI Ref ID J:152061]

Patel DR; Kaplan MH; Chang CH. 2004. Altered Th1 cell differentiation programming by CIITA deficiency. J Immunol 173(9):5501-8. [PubMed: 15494498]  [MGI Ref ID J:93745]

Pihlgren M; Silva AB; Madani R; Giriens V; Waeckerle-Men Y; Fettelschoss A; Hickman DT; Lopez-Deber MP; Ndao DM; Vukicevic M; Buccarello AL; Gafner V; Chuard N; Reis P; Piorkowska K; Pfeifer A; Kundig TM; Muhs A; Johansen P. 2013. TLR4- and TRIF-dependent stimulation of B lymphocytes by peptide liposomes enables T cell-independent isotype switch in mice. Blood 121(1):85-94. [PubMed: 23144170]  [MGI Ref ID J:192819]

Qiao Y; Zhu L; Sofi H; Lapinski PE; Horai R; Mueller K; Stritesky GL; He X; Teh HS; Wiest DL; Kappes DJ; King PD; Hogquist KA; Schwartzberg PL; Sant'Angelo DB; Chang CH. 2012. Development of promyelocytic leukemia zinc finger-expressing innate CD4 T cells requires stronger T-cell receptor signals than conventional CD4 T cells. Proc Natl Acad Sci U S A 109(40):16264-9. [PubMed: 22988097]  [MGI Ref ID J:190112]

Romagnoli PA; Premenko-Lanier MF; Loria GD; Altman JD. 2013. CD8 T cell memory recall is enhanced by novel direct interactions with CD4 T cells enabled by MHC class II transferred from APCs. PLoS One 8(2):e56999. [PubMed: 23441229]  [MGI Ref ID J:199409]

Rubino SJ; Geddes K; Magalhaes JG; Streutker C; Philpott DJ; Girardin SE. 2013. Constitutive induction of intestinal Tc17 cells in the absence of hematopoietic cell-specific MHC class II expression. Eur J Immunol 43(11):2896-906. [PubMed: 23881368]  [MGI Ref ID J:203009]

Sawa S; Kamimura D; Jin GH; Morikawa H; Kamon H; Nishihara M; Ishihara K; Murakami M; Hirano T. 2006. Autoimmune arthritis associated with mutated interleukin (IL)-6 receptor gp130 is driven by STAT3/IL-7-dependent homeostatic proliferation of CD4+ T cells. J Exp Med 203(6):1459-70. [PubMed: 16717113]  [MGI Ref ID J:124381]

Sofi MH; Liu Z; Zhu L; Yu Q; Kaplan MH; Chang CH. 2010. Regulation of IL-17 expression by the developmental pathway of CD4 T cells in the thymus. Mol Immunol 47(6):1262-8. [PubMed: 20080304]  [MGI Ref ID J:158374]

Soong L; Chang CH; Sun J; Longley BJ Jr; Ruddle NH; Flavell RA; McMahon-Pratt D. 1997. Role of CD4+ T cells in pathogenesis associated with Leishmania amazonensis infection. J Immunol 158(11):5374-83. [PubMed: 9164958]  [MGI Ref ID J:64283]

Taniguchi RT; Devoss JJ; Moon JJ; Sidney J; Sette A; Jenkins MK; Anderson MS. 2012. Detection of an autoreactive T-cell population within the polyclonal repertoire that undergoes distinct autoimmune regulator (Aire)-mediated selection. Proc Natl Acad Sci U S A 109(20):7847-52. [PubMed: 22552229]  [MGI Ref ID J:184783]

Tazawa H; Irei T; Tanaka Y; Igarashi Y; Tashiro H; Ohdan H. 2013. Blockade of invariant TCR-CD1d interaction specifically inhibits antibody production against blood group A carbohydrates. Blood 122(15):2582-90. [PubMed: 23943651]  [MGI Ref ID J:203264]

Trautmann T; Kozik JH; Carambia A; Richter K; Lischke T; Schwinge D; Mittrucker HW; Lohse AW; Oxenius A; Wiegard C; Herkel J. 2014. CD4+ T-cell help is required for effective CD8+ T cell-mediated resolution of acute viral hepatitis in mice. PLoS One 9(1):e86348. [PubMed: 24466045]  [MGI Ref ID J:212565]

Winer DA; Winer S; Shen L; Wadia PP; Yantha J; Paltser G; Tsui H; Wu P; Davidson MG; Alonso MN; Leong HX; Glassford A; Caimol M; Kenkel JA; Tedder TF; McLaughlin T; Miklos DB; Dosch HM; Engleman EG. 2011. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med 17(5):610-7. [PubMed: 21499269]  [MGI Ref ID J:171607]

Xu Y; Luchsinger L; Lucey EC; Smith BD. 2011. The effect of class II transactivator mutations on bleomycin-induced lung inflammation and fibrosis. Am J Respir Cell Mol Biol 44(6):898-905. [PubMed: 20705943]  [MGI Ref ID J:185026]

Xu Y; McDonald J; Perloff E; Buttice G; Schreiber BM; Smith BD. 2007. Collagen and major histocompatibility class II expression in mesenchymal cells from CIITA hypomorphic mice. Mol Immunol 44(7):1720-32. [PubMed: 16982097]  [MGI Ref ID J:115938]

Yang SJ; Ahn S; Park CS; Holmes KL; Westrup J; Chang CH; Kim MG. 2006. The quantitative assessment of MHC II on thymic epithelium: implications in cortical thymocyte development. Int Immunol 18(5):729-39. [PubMed: 16569676]  [MGI Ref ID J:108547]

Yee CS; Yao Y; Li P; Klemsz MJ; Blum JS; Chang CH. 2004. Cathepsin E: a novel target for regulation by class II transactivator. J Immunol 172(9):5528-34. [PubMed: 15100295]  [MGI Ref ID J:89650]

Yee CS; Yao Y; Xu Q; McCarthy B; Sun-Lin D; Tone M; Waldmann H; Chang CH. 2005. Enhanced production of IL-10 by dendritic cells deficient in CIITA. J Immunol 174(3):1222-9. [PubMed: 15661876]  [MGI Ref ID J:96421]

Young HY; Zucker P; Flavell RA; Jevnikar AM; Singh B. 2004. Characterization of the role of major histocompatibility complex in type 1 diabetes recurrence after islet transplantation. Transplantation 78(4):509-15. [PubMed: 15446308]  [MGI Ref ID J:107051]

Zhang B; Kracker S; Yasuda T; Casola S; Vanneman M; Homig-Holzel C; Wang Z; Derudder E; Li S; Chakraborty T; Cotter SE; Koyama S; Currie T; Freeman GJ; Kutok JL; Rodig SJ; Dranoff G; Rajewsky K. 2012. Immune Surveillance and Therapy of Lymphomas Driven by Epstein-Barr Virus Protein LMP1 in a Mouse Model. Cell 148(4):739-51. [PubMed: 22341446]  [MGI Ref ID J:181546]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $3300.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $4290.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.

    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

General Supply Notes

Control Information

  Control
   001976 NOD/ShiLtJ
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.

Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.8)